Table 1. Peptides/proteins encapsulated in polymeric nanoparticles for ApoE-mediated brain targeting.a .
| Drug | Disease/Effect of drug | Nanoparticular formulation | Type of ApoE-functionalization | In Vivo | [Ref.] |
|---|---|---|---|---|---|
| Dalargin (Hexapeptide) | Analgesia | PBCA | Indirect by PS80 coating | yes | [43–45, 51, 74, 110, 119] |
| PBCA | Indirect by different PS coatings | yes | [46, 119a] | ||
| PBCA | Indirect by PEG 20000 and/or PS80 coating | yes | [52] | ||
| PBCA | Coating with ApoE (and PS80) | yes | [59–60] | ||
| Kyotorphin (Dipeptide) | Analgesia | PBCA | Indirect by PS80 coating | yes | [74] |
| Morphiceptin (Tetrapeptide) | Analgesia | PBCA | Indirect by PS80 coating | yes | [120] |
| Endomorphin-1 (Tetrapeptide) | Analgesia | PBCA | Indirect by PS80 coating | yes | [121] |
| Nerve growth factor | Alzheimer’s disease Parkinson’s disease |
PBCA | Indirect by PS80 coating | yes | [75–76] |
| Stroke | Iron oxide and HSA | Covalent linkage of ApoE | yes | [77] | |
| BDNF | Traumatic brain injury | PLGA | Indirect by poloxamer 188-coating | yes | [78] |
| Arylsulfatase A | Metachromatic leukodystrophy | PBCA | Indirect by PS80 coating | no | [122] |
| PLA | Indirect by poloxamer 188-coating | no | [122] | ||
| PLGA | Indirect by poloxamer 188-coating | no | [122] | ||
| HSA | Indirect by PS80 coating | no | [122] |
a
Abbreviation: PS80 = polysorbate 80.